DDInter119 DDInter1261
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier.
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Neratinib
Naloxegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Griseofulvin
Naloxegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Naloxegol {u} may lead to a major life threatening interaction when taken with {v} Conivaptan
Naloxegol {u} may lead to a major life threatening interaction when taken with {v} Stiripentol
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Naloxegol may lead to a major life threatening interaction when taken with Conivaptan
Naloxegol may lead to a major life threatening interaction when taken with Stiripentol